How the Capitol Forum Brought Down Zynex (Second Request)

For a minute, take yourself back to the summer of 2021.

It was a few months after the COVID-19 shots had been distributed, but a lot of people still had that bunker mentality in them.

During the pandemic, hobbies became a big thing, and one of the more interesting ones was stock trading.

Thanks to apps like Robinhood and the boredom of isolation, the stock market was flooded with amateur traders back then.

And one of the most prominent venues they went for tips was CNBC's Mad Money.

Booyah, Jim.

First time caller.

I loved your show.

Thank you.

Mad Money's hosted by this guy, Jim Cramer, who doles out stock advice like he's tossing out t-shirts at a football game.

It is time! It's time for the lightning

round! In June of 2021, Cramer was hosting something he called the lightning round, where viewers called in to get his instant analysis of a company's stock.

And that day, one guy called in to ask about a company called Zynex.

Several years ago, I took some mad money and invested in this stock as a spec play against the use of post-surgery opioids.

I feel the stock should get back on track now.

Kramer's a well-known fixture in financial news whose wisdom is questionable.

No, your analysis is spot on, sir.

It's time to buy, not sell your stock.

But that company he was talking about, Zynex, it was a medical device company that was on the rise.

Two years before Kramer talked about it on his show, Zynex and their CEO, Thomas Sandgard, rang the bell at the New York Stock Exchange.

In the video, you can see how excited Sandgard is.

As soon as he can, he slams his hand down on the bell and claps giddily like a kid on Christmas.

And there was good reason why.

Zynex made Sandgard rich, so rich he could live out his childhood fantasies.

What you're hearing is Thomas Sandgaard, Zynex's founder, playing the guitar in an empty English soccer stadium.